MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a generally positive outlook, with a notable decrease in operating and net losses, and strong cash reserves. The Q&A highlights confidence in Exo's future contributions and sustained performance in GPS and Confirm products. Despite some avoidance in addressing ASP declines, the strategic focus on Exo and sales team expansion suggests growth potential. The absence of material negative factors and optimistic guidance point towards a positive stock price movement in the near term.
Key Financial Performance
Q3 Revenue $27.4 million, representing an 18% growth over 2024. The growth occurred despite the decision to forego focus on the previously planned Germline offering.
Adjusted EBITDA $1 million, compared to a negative $3.8 million for the third quarter of 2024. This improvement reflects better operational efficiency and growth in sales.
Total Operating Expenses (OpEx) Flat for Q3 and year-to-date over 2024, up a mere 1% on 20% year-to-date top-line growth while absorbing material acquisition-related expenses.
Total Billable Volume Approximately 33,000 tests, representing a 37% growth versus the prior year quarter. Tissue-based tests increased by 18%, and liquid-based tests increased by 65%.
Gross Profit $17.9 million, an increase of 25% compared to $14.3 million for the third quarter of 2024. Gross margins improved to 65.2% from 61.2%, attributed to test mix and operational efficiencies.
Operating Loss $2.6 million, a decline of 57% compared to $6.1 million for the third quarter of 2024. This was driven by growth in sales and gross profit.
Net Loss $8 million, a decrease of 28% compared to $11.2 million for the prior year. This reflects improved financial performance.
Cash and Cash Equivalents $32 million as of September 30, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Exosome Diagnostics acquisition: Acquired Exosome Diagnostics business, enhancing MDxHealth's precision diagnostics in urology.
ExoDx test: Transitioning Select customers to ExoDx test by year-end, offering optimal and clinically actionable results.
Sales force expansion: Expanded sales organization from 50 to 60 direct sales reps across 8 regions to optimize cross-selling opportunities.
Revenue growth: Achieved 18% revenue growth in Q3 2025 compared to 2024, with $27.4 million in revenue.
Gross margin improvement: Improved gross margins to 65.2% in Q3 2025 from 61.2% in Q3 2024 due to test mix and operational efficiencies.
Laboratory operations: Integrated three labs in California, Texas, and Massachusetts to enhance operational efficiency and quality.
Germline market entry deferred: Postponed Germline market entry to focus on ExoDx integration and customer engagement.
Strategic opportunities from ExoDx: Evaluating strategic opportunities from ExoDx platform for urology and potential partnerships.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Integration of ExoDx acquisition: The integration of the ExoDx acquisition is a high priority and involves operational and sales force integration. Challenges include ensuring seamless integration, maintaining customer engagement, and converting Select customers to ExoDx by year-end. Any delays or inefficiencies could disrupt operations and customer satisfaction.
Focus on operational efficiency: The company is focusing on improving gross margins and operational efficiency across its expanded laboratory operations. Challenges include maintaining high performance metrics and achieving operational excellence while integrating new facilities and systems.
Germline market entry delay: The company has set aside its entry into the Germline market, which was expected to contribute materially to revenue in the second half of the year. This delay could impact revenue growth and strategic plans.
Capital allocation discipline: The company emphasizes disciplined capital allocation to reduce cash usage. Any mismanagement or unforeseen expenses could strain financial resources and impact profitability.
Customer experience and service standards: Maintaining high customer service standards during operational changes and integration processes is critical. Any decline in service quality could harm the company's reputation and customer trust.
Regulatory and quality compliance: The company operates in a highly regulated industry, and any lapses in quality or regulatory compliance during the integration and operational expansion could lead to legal or financial repercussions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Maintaining 2025 revenue guidance of $108 million to $110 million despite setting aside the Germline market entry.
Integration of ExoDx Acquisition: Integration of ExoDx acquisition is a priority for Q4, focusing on operational and sales force integration, customer engagement, and transitioning Select customers to ExoDx by year-end.
Sales Expansion: Strategic expansion of sales organization from 50 to 60 direct sales reps across 8 regions to optimize cross-selling opportunities and drive growth.
Operational Efficiency: Focus on improving gross margins and operational efficiency through laboratory integration and advanced information systems.
Future Product and Market Opportunities: Actively evaluating strategic opportunities from ExoDx platform in multiple cancers, including prostate, for potential internal development or partnerships.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What was the contribution of Exo in the quarter, and how does it relate to the company's product portfolio changes?
A:The company did not expect material contribution from Germline in the first half of the year but anticipated it in Q3 and Q4. However, with the ExoDx acquisition closing at the end of Q3, the focus shifted to Exo. There was no material contribution from Exo in Q3, but the company is confident in meeting or exceeding revenue guidance for Q4. The transition involved moving customers from Select to Exo, and the company believes this strategy will ensure successful integration and growth.
Q:How did GPS perform in the quarter, and what is the outlook for Q4?
A:GPS and Confirm contributed to 18% growth in tissue, which is significantly ahead of market growth. The company observed a slight patient flow slowdown in biopsies but maintained strong performance. Tissue revenue weighting decreased slightly due to strong liquid growth, but margins held at 65%, which is above expectations. The company is confident in sustaining this performance.
Q:What is the expected contribution of Exo compared to Germline and Select tests?
A:The company expects Exo's contribution to be around the same level as Germline and Select tests. The core Exo business is expected to grow over the next 2-3 quarters, with a renewed focus on this market opportunity. The company remains confident in its strategy and growth potential.
Q:What analysis was done on customer bases to inform sales team expansion?
A:The company analyzed growth trends, crossover opportunities between Exo and tissue products, and historical ordering trends. They also considered sales talent and customer base mix. This analysis informed the decision to expand the sales team, which is expected to drive productivity and support the P&L.
Q:What is the opportunity and rationale behind integrating client service and RCM initiatives?
A:The integration of laboratory operations, client services, and revenue cycle management (RCM) is aimed at aligning processes and expectations to predict and project the business effectively. This integration is a key focus for Q4 to ensure efficiency and support for customers, with the goal of maintaining strong P&L performance.
Q:Why was there a decline in ASP on the tissue side, and is it significant?
A:The company does not report ASP by test and sees variability each quarter. They do not view the decline as significant or notable and remain confident in their payer mix and revenue cycle management.
Q:Has anything changed regarding the expected $20 million contribution from Exo in 2026?
A:Nothing has changed. The company still expects Exo to contribute at least $20 million in 2026, and this view remains unchanged. They also anticipate accelerating revenue growth from 20% to close to 30%.
Q:Why is the Germline test being set aside, and will it be revisited?
A:The Germline test was set aside due to a strategic decision to focus on other priorities, such as the Exo acquisition and integration. The company believes the Germline market remains an opportunity and plans to revisit it in the future.
Q:Will Exo be accretive to gross margins in 2026, and is 65% gross margin sustainable?
A:The company expects Exo to be neutral to accretive to gross margins in 2026. While 65% gross margin is ahead of expectations, the company is optimistic about sustaining this level but will provide a clearer view at the beginning of the year.
Q:What changes were made to the commercial team with the Exo acquisition?
A:The company added 10 direct reps from Exo, increasing the sales team from 50 to 60. Territories were adjusted to strengthen performance, and the process was informed by lessons learned from previous acquisitions. The company is confident in the new team structure.
Q:Has there been any negative feedback from customers switching from Select to Exo?
A:It is too early to comment, but the company is confident that the switch will not create friction, as Exo is considered a better test.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the decline in ASP on the tissue side, providing only general comments about variability and not offering specific reasons or data. Additionally, they did not provide clear guidance on the expected contribution of Exo in 2026, emphasizing that their views were not intended as guidance. They also avoided providing specific details about the integration process and early performance of the new sales team.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounting remark
California Texas
Conference Instructions
Conference today
ConfirmMDx GPS
Diagnostics industry
ExoDx Massachusetts
ExoDx Revenues
ExoDx Select
ExoDx acquisition
ExoDx customer
ExoDx entry
ExoDx opportunity
ExoDx test
Exosome
Germline
Select ExoDx
class
customer engagement
customer experience
date
efficiency
end
integration
margin
material
operation
patient clinician
percentage
perspective
point
productivity
quality
rep region
sale rep
service
standard
MDXH Transcript
MDxHealth SA (MDXH) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals several concerning factors: a widening operating loss, a significant net loss, and a decrease in cash reserves. Although management expressed confidence in their core business and provided optimistic guidance, the Q&A highlighted unresolved financial issues and vague responses from management. These factors, combined with the absence of strong positive catalysts, suggest a negative sentiment, likely resulting in a stock price decline of -2% to -8% over the next two weeks.
MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call presents a mixed picture. Positive elements include revenue growth, improved gross margins, and strategic plans for sales expansion and operational efficiency. However, concerns arise from increased operating losses, complex integration of ExoDx, and lack of specific guidance details. Q&A insights highlight management's confidence in growth but also reveal uncertainties in achieving financial targets. The market may react cautiously, balancing optimism about strategic initiatives with concerns over financial health and execution risks. Given these factors, a neutral stock price movement is anticipated.
MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call presents a generally positive outlook, with a notable decrease in operating and net losses, and strong cash reserves. The Q&A highlights confidence in Exo's future contributions and sustained performance in GPS and Confirm products. Despite some avoidance in addressing ASP declines, the strategic focus on Exo and sales team expansion suggests growth potential. The absence of material negative factors and optimistic guidance point towards a positive stock price movement in the near term.
MDxHealth SA (MDXH) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call presents a mixed picture: strong revenue growth and improved gross margins are offset by increased net losses and significant financial obligations. The absence of a share repurchase program and concerns over sustaining growth in a competitive market further temper positive sentiment. While management's optimistic guidance and effective market strategy are promising, the lack of specific guidance and financial challenges maintain a neutral outlook for the stock price in the near term.
MDXH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
